Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 17, Issue 12, Pages 1955-1962Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543780802528609
Keywords
antisense oligonucleotide; cancer; clusterin; custirsen; prostate cancer
Categories
Ask authors/readers for more resources
Background: Clusterin is a stress-induced cytoprotective chaperone protein, regulated by HSF1, and functions similarly to a small heat-shock protein. Clusterin is expressed in a variety of cancers and associated with broad-spectrum treatment resistance. Custirsen (OGX-011) is a 2'-methoxyethyl modified phosphorothioate antisense oligonucleotide that is complementary to clusterin mRNA; it is currently in clinical trials for patients with cancer. Objective/methods: To review the literature on the role of clusterin in cancer progression and treatment resistance, and to summarize completed and ongoing clinical trials with custirsen. Results/conclusions: Custirsen is well tolerated in humans and biologically active in inhibiting expression of clusterin in patients with cancer. Randomized trials of custirsen in combination with chemotherapy are planned in patients with castration-resistant prostate cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available